News
11-23-2011, 10:00 PM
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.
More... (http://www.news-medical.net/news/20111123/Advaxis-completes-ADXS-HER2-pre-IND-meeting-with-FDA.aspx)
More... (http://www.news-medical.net/news/20111123/Advaxis-completes-ADXS-HER2-pre-IND-meeting-with-FDA.aspx)